BioAdaptives (BDPT) 10-K 1 May 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2019USD ($)shares
Document And Entity Information
Entity Registrant Name	BIOADAPTIVES, INC.
Entity Central Index Key	0001575142
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2019
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Common Stock Shares Outstanding | shares	18,576,379
Entity Public Float | $	$ 2,263,470
Entity File Number	000-54949
Entity Address Address Line 1	2620 Regatta Drive
Entity Address Address Line 2	Suite 102
Entity Address Postal Zip Code	0000
Entity Tax Identification Number	46-2592228
Entity Address City Or Town	Las Vegas
Local Phone Number	659-8829
City Area Code	702
Entity Address State Or Province	DE
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 12,313	$ 56,215
Marketable securities	772	3,987
Inventory	11,128	49,857
Total Current Assets	24,213	110,059
TOTAL ASSETS	24,213	110,059
Current Liabilities:
Accounts payable and accrued liabilities	29,954	53,951
Derivative liabilities	464,024	662,038
Current portion of convertible notes - net of discount of $71,607 and $0	312,893
Notes Payable	7,218
Note payable - related party	50,000
Total Current Liabilities	864,089	715,989
Convertible notes - net of discount of $0 and $223,189		87,811
Total Liabilities	864,089	803,800
Stockholders' Deficit:
Preferred stock, ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)
Common stock ($.0001 par value, 100,000,000 shares authorized; 18,576,379 and 18,096,169 shares issued and outstanding, and 362,390 and 275,502 issuable, respectively)	1,894	1,837
Additional paid-in capital	3,917,147	3,824,412
Accumulated deficit	(4,758,917)	(4,519,990)
Total Stockholders' Deficit	(839,876)	(693,741)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 24,213	$ 110,059

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Current portion of convertible notes - net of discount	$ 71,607	$ 0
Convertible notes - net of discount	$ 0	$ 223,189
Stockholders' Deficit
Preferred stock, shares par value	$ .0001	$ .0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares par value	$ .0001	$ .0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	18,576,379	18,096,169
Common stock, shares outstanding	18,576,379	18,096,169
Common stock, shares issuable	362,390	275,502

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 9,934
Cost of revenue	5,049
Gross Profit	4,885
Operating Expenses
General and administrative	88,933	166,222
Professional fees	57,567	219,034
Stock based compensation	92,792	272,685
Total Operating Expenses	239,292	657,941
Other Income (Expense)
Unrealized loss on marketable securities	(3,215)	784
Interest expense	(199,319)	(247,885)
Change in fair value of derivative liabilities	198,014	(501,620)
Total Other Income (Expense)	(4,520)	(748,722)
Loss before income taxes	(238,927)	(1,406,663)
Net loss	$ (238,927)	$ (1,406,663)
Net Loss Per Common Share:
Basic and Diluted	$ (0.01)	$ (0.08)
Weighted Average Number of Common Shares Outstanding:
Basic and diluted shares	18,650,396	16,973,686

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Accumulated other comprehensive loss
Balance, shares at Dec. 31, 2017			15,578,262
Balance, amount at Dec. 31, 2017	$ (3,505)		$ 1,559	$ 3,115,273	$ (3,054,991)	$ (58,336)
Adoption of accounting standards					(58,336)	58,336
Common stock issued for cash
Common stock issued for service, shares			570,758
Common stock issued for service, amount	101,995		$ 57	101,938
Common stock issued for service - related party, shares			644,744
Common stock issued for service - related party, amount	118,325		$ 64	118,261
Common stock issued with convertible notes, shares			107,000
Common stock issued with convertible notes, amount	22,210		$ 10	22,200
Common stock issued for conversion of debt, shares			1,470,907
Common stock issued for conversion of debt, amount	139,150		$ 147	139,003
Resolution of derivative liabilities	285,568			285,568
Warrant issued for service	52,365			52,365
Gain on sales of asset to related party	32,000			32,000
Reclassification of derivative liability from additional paid in capital	(42,196)			(42,196)
Net loss for the period	(1,406,663)				(1,406,663)
Balance, shares at Dec. 31, 2018			18,371,671
Balance, amount at Dec. 31, 2018	(693,741)		$ 1,837	3,824,412	(4,519,900)
Common stock issued for service - related party, shares			637,856
Common stock issued for service - related party, amount	92,792		$ 64	92,728
Net loss for the period	(238,927)				(238,927)
Cancellation of shares, shares			(70,758)
Cancellation of shares, amount			$ (7)	7
Balance, shares at Dec. 31, 2019			18,938,769
Balance, amount at Dec. 31, 2019	$ (839,876)		$ 1,894	$ 3,917,147	$ (4,758,917)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (238,927)	$ (1,406,663)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		101,995
Stock-based compensation - related party	92,792	118,325
Warrants issued for service		52,365
Bad debt		19,381
Change in fair value of derivative liabilities	(198,014)	501,620
Amortization of debt discount	158,082	202,811
Unrealized loss on investments in marketable securities	3,215	(784)
Changes in operating assets and liabilities:
Inventory	38,729	(49,857)
Prepaid expense and other current assets		(19,381)
Accounts payable and accrued liabilities	(23,997)	78,043
Net Cash Used in Operating Activities	(168,120)	(420,145)
CASH FLOWS FROM INVESTING ACTIVITIES
Sales of assets		32,000
Net cash Provided by Investing Activities		32,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Notes payable	15,800
Repayments of notes payable	(8,582)
Proceeds from Notes payable - related party	50,000
Proceeds from Convertible notes	67,000	426,000
Net Cash Provided by Financing Activities	124,218	426,000
Net change in cash	(43,902)	55,855
Cash at beginning of period	56,215
Cash at end of period	12,313	56,215
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest	47,864	12,839
NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount		403,789
Issuance of common stock for conversion of debt and accrued interest		139,150
Reclassification of derivative liability from additional paid in capital due to tainted instruments		42,196
Gain On Sale of Asset to related party		32,000
Resolution of derivative liability upon conversion of debt		285,568
Common stock issued in conjunction with convertible notes		22,210
Cancellation of common stock	$ 7

DESCRIPTION OF BUSINESS AND HIS

DESCRIPTION OF BUSINESS AND HISTORY	12 Months Ended
	Dec. 31, 2019
DESCRIPTION OF BUSINESS AND HISTORY
1. DESCRIPTION OF BUSINESS AND HISTORY	Description of business BioAdaptives, Inc. (formerly known as APEX 8 Inc.) (“BioAdaptives”,” Company”) was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products and strategies that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages. Our base of products and intellectual property are designed to aid in cognition, focus, fatigue reduction, increased testosterone, improved overall emotional and physical wellness, healing, and anti-ageing and include patent pending solutions in the form of devices and nutraceuticals, The Company’s strategy is to develop a position as a leader in supplying science-based quality nutraceutical products to an aging population within developed countries such as the United States, Canada, APAC countries, such as China, Japan, Korea, Singapore, Taiwan, Australia and New Zealand, as well as both Western and Eastern Europe, while continuing to create new innovative, health inspired products to start generating growth in sales and profitability. Some of the products have proven to be as effective or even more effective on horses and dogs than on humans and this has caused the Company to expand the target market to include dogs and horses. Since 2014, BioAdaptives®, has been engaged in the research of primitive cells, including stem cells and their derivatives and natural ingredients which may encourage its proliferation. Such studies were conducted both on human and animals, in particular, canine and equine. The results have been encouraging. More in depth studies on this and other wellness aspects such as anti-aging and sports performance are scheduled. On May 22, 2019, the Company moved its corporate office to 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128, but maintained fulfillment facilities at 4385 Cameron Street, Suite B, Las Vegas, NV 89103.

SUMMARY OF SIGNIFICANT POLICIES

SUMMARY OF SIGNIFICANT POLICIES	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT POLICIES
2. SUMMARY OF SIGNIFICANT POLICIES	Basis of Presentation The Company represents its consolidated financial statements were prepared in accordance with US GAAP and the rules of the Securities and Exchange Commission and that, in the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations are historical and not necessarily indicative of the results to be expected for any future period. Consolidation The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Blenders Choice Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.” Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and cash equivalents Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high credit quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value. As of December 31, 2019, and 2018, the Company has no cash equivalents. Investment Securities In January 2016, the FASB issued ASU 2016-01, Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), which addresses certain aspects of the recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 was effective for the Company beginning January 1, 2018 and we are now recognizing any changes in the fair value of certain equity investments in net income as prescribed by the new standard rather than in other comprehensive income ("OCI"). We recognized a cumulative effect adjustment to increase the opening balance of accumulative deficit as of January 1, 2018 by $58,336. Equity securities are classified as available for sale. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. In accordance with Accounting Standards Codification (“ASC”) 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary. Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. There were no potentially dilutive securities outstanding during the periods presented. Revenue recognition Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. Cost of revenue Cost of revenue includes the inventory purchased from a related party. Inventory Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at December 31, 2019 and 2018, the Company determined that no reserve was required. Stock-based compensation The Company accounts for stock-based compensation arrangements with employees, nonemployee directors and consultants using a fair value method, which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options, on a straight-line basis over the requisite service period in the Company’s consolidated statements of operations. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant. Financial Instruments and Fair Value Measurements As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level at December 31, 2019 and 2018, measured at fair value on a recurring basis: Fair Value Measurements as of December 31, 2019 Using: Total Carrying Value as of December 31, Quoted Market Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs 2019 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 772 $ 772 $ - $ - Liabilities Derivative liabilities $ 464,024 464,024 Fair Value Measurements as of December 31, 2018 Using: Total Carrying 2018 Quoted Market Significant Other (Level 2) Significant (Level 3) Assets: Equity Securities $ 3,987 $ 3,987 $ - $ - Liabilities Derivative liabilities $ 662,038 $ - $ - $ 662,038 Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Concentration of credit risk Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings. Income taxes The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more- likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives. The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the financial results of operations improve, and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance. Significant judgment is required in evaluating the Company’s tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2019
GOING CONCERN
3. GOING CONCERN	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $4,758,917 as of December 31, 2019. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company’s contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties. In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

MARKETABLE SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2019
MARKETABLE SECURITIES
4. MARKETABLE SECURITIES	Equity securities at December 31, 2019 and 2018, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $772 and $3,987, respectively.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2019
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	Accounts payable and accrued liabilities at December 31, 2019 and 2018 consists of the following. December 31, December 31, 2019 2018 Accounts payable $ 1,297 $ 39,724 Credit card 20,214 719 Accrued interest 2,457 8,185 Accrued liabilities 5,986 5,323 $ 29,954 $ 53,951

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2019
CONVERTIBLE NOTES
6. CONVERTIBLE NOTES	Convertible notes at December 31, 2019 and 2018 consist of the following: December 31, December 31, 2019 2018 Convertible Notes - originated in April 2018 $ 95,000 $ 95,000 Convertible Notes - originated in June 2018 166,000 166,000 Convertible Notes - originated in October 2018 50,000 50,000 Convertible Notes - issued fiscal year 2019 73,500 - Total convertible notes payable 384,500 311,000 Less: Unamortized debt discount (71,607 ) (223,189 ) Total convertible notes 312,893 87,811 Less: current portion of convertible notes 312,893 - Long-term convertible notes $ - $ 87,811 The Company recognized amortization expense related to the debt discount of $158,082 and $202,811 for the year ended December 31, 2019 and 2018, respectively, which is included in interest expense in the statements of operation. For the year ended December 31, 2019 and 2018, the interest expense on convertible notes was $39,457 and $45,074, respectively. As of December 31, 2019 and 2018, the accrued interest was $1,391 and $8,183, respectively. Convertible Notes – Issued during the year ended December 31, 2018 During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of convertible notes are summarized as follows: · Term two years; · Annual interest rates 12%; · Convertible at the option of the holders at any time · Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price. Convertible Notes – Issued during the year ended December 31, 2019 During the year ended December 31, 2019, the Company issued a total principal amount of $73,500 in convertible notes for cash proceeds of $67,000. The terms of convertible notes are summarized as follows: · Term one years; · Annual interest rates 10%; · Convertible at 180 days from issuance · Conversion prices are58% multiplied by the lowest trading price during the 20 trading day period ending on the latest complete training day prior to the conversion date.

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2019
DERIVATIVE LIABILITIES
7. DERIVATIVE LIABILITIES	The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options. Fair Value Assumptions Used in Accounting for Derivative Liabilities. ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item. The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of December 31, 2019. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model. For the year ended December 31, 2019 and 2018, the estimated fair values of the liabilities measured on a recurring basis are as follows: Year Ended Year ended December 31, December 31, 2019 2018 Expected term 0.22 - 1.43 years 1.22 - 2.01 years Expected average volatility 229% - 320% 265% - 309% Expected dividend yield - - Risk-free interest rate 1.55% - 2.40% 2.27% - 2.88% The following table summarizes the changes in the derivative liabilities during the year ended December 31, 2019 and 2018 Fair Value Measurements Using Significant Observable Inputs (Level 3) Balance - December 31, 2017 $ - Addition of new derivatives recognized as debt discounts 403,790 Addition of new derivatives recognized as loss on derivatives 452,943 Settled on issuance of common stock (285,568 ) Reclassification from APIC to derivative due to tainted instruments 42,196 Loss on change in fair value of the derivative 48,677 Balance - December 31, 2018 $ 662,038 Gain on change in fair value of the derivative (198,014 ) Balance - December 31, 2019 $ 464,024 The aggregate loss on derivatives during the year ended December 31, 2019 and 2018 was as follows. Year Ended December 31, 2019 2018 Day one loss due to derivative liabilities on convertible notes $ - $ 452,943 (Gain) loss on change in fair value of the derivative liabilities (198,014 ) 48,677 $ (198,014 ) $ 501,620

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2019
NOTES PAYABLE
8. NOTES PAYABLE	On August 1, 2019, the Company issued a note payable of $11,900 to a third party. The repayment amount is $12,852 and the term is 6 months. During the year ended December 31, 2019, the Company repaid $8,588 including interest expense of $656. On October 24, 2019, the Company issued a note payable of $3,900 to a third party. The repayment amount is $4,212 and the term is 6 months. During the year ended December 31, 2019, the Company repaid $709 including interest expense of $59. As of December 31, 2019, the Company recorded notes payable of $7,218 and accrued interest of $256.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2019
STOCKHOLDERS' EQUITY
9. STOCKHOLDERS' EQUITY	Preferred Stock The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of December 31, 2019, and 2018, no shares of preferred stock had been issued. Common Stock The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock as of December 31, 2019. During the year ended December 31, 2019, the Company issued 480,210 shares of restricted common stock to Dr. Edward Jacobs, who is our CEO, as his compensation from August 1, 2018 to June 30, 2019. During the year ended December 31, 2019, the Company recorded 352,390 shares of common stock issuable valued at $42,000 based on an employment agreement – related party transaction (See Note 10). During the year ended December 31, 2019, the Company settled 70,758 shares of common stock issuable for consulting service and cancelled 70,758 shares of common stock. During the year ended December 31, 2018, the Company issued 2,038,975 shares of common stock as follows, · 1,250,000 shares to unrelated party for a subscription receivable of $100,000. On June 30, 2018, the issuance of 1,250,000 shares was cancelled. · 107,000 shares of common stock, with a value of $22,110, as additional consideration for the issuance of convertible notes (see Note 6) · 231,975 shares of common stock valued at $44,095 for consulting service · 450,000 shares of common stock valued at $83,325 based on an employment agreement As of December 31, 2019, and 2018, there were 18,576,379 and 18,096,169 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of December 31, 2019 and 2018, there were 362,390 shares and 275,502 shares of the Company’s common stock issuable, respectively. Warrant During the year ended December 31, 2018, the Company entered into an agreement with consultant to provide the Company with consulting services in exchange for 2-year warrant to purchase 200,000 shares of common stock with an exercise price of $0.1 per share. The Company recognized a warrant expense of $52,365, as stock-based compensation and additional paid-in capital. The Company determined that the warrants qualify for derivative accounting as a result of the related issuance of the convertible note on in April 2018, which had no express limit on the number of shares to be delivered upon future settlement of the conversion options (see Note 7). The following table summarizes information relating to outstanding and exercisable stock options as of December 31, 2019: Warrants Outstanding Warrants Exercisable Number of Contractual life Number of Shares (in years) Exercise Price Shares Exercise Price 200,000 0.22 $ 0.10 200,000 $ 0.10 As of December 31, 2019, the aggregate intrinsic value of warrants outstanding was approximately $7,720 based on the closing market price of $0.1386 on December 31, 2019.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2019
RELATED PARTY TRANSACTIONS
10. RELATAED PARTY TRNSACTIONS	On June 1, 2014, the Company entered into a rental agreement with Ferris for the corporate office. Monthly rent is $1,500. The term of the lease is month to month. On April 1, 2017, the Company entered into a new rental agreement with Ferris for the corporate office. Monthly rent is $1,500. The term of the lease is one year until March 31, 2018. During the year ended December 31, 2018, the Company sold all rights to the Excel Dog treat trademark, research, and videos to Ferris Holding, Inc for $32,000 and recorded a gain on the sale to related party of $32,000 as additional paid in capital. The sales of all rights qualified as a discontinued operation of the Company. During the year ended 2018, there were no revenue and expenses related to this operation. Employee agreements In June 2018, the Company originally entered into an employment agreement with Dr. Edwards E. Jacobs, Jr.,our CEO. A base compensation is $10,000 monthly and 100,000 shares of common stock valued at $27,500. In October 2018, the agreement was amended to a base compensation is $7,000 in cash or equivalent in common stock. During year ended December 31, 2019, the Company recorded Stock based compensation of $84,000 (See Note 9). In August 2019, the Company entered into an employment agreement with Robert W. Ellis, our president. A base compensation is $5,000 in cash per monthly and 250,000 shares to be issued on August 31, 2020 valued at $26,375. During year ended December 31, 2019, the Company recorded Stock based compensation of $8,792 and accrued liability of $5,000. In September 2019, the Company entered into an employment agreement with Ronald Lambrecht, our Chief Financial Officer. A base compensation is $5,000 equivalent in common stock monthly and 100,000 shares to be issued on September 30, 2020 valued at $11,010. The service will be provided from January 2, 2020. Notes payable – related party During the year ended December 31, 2019, the Company issued a total principal amount of $50,000 notes to the company owned by our CEO. The note is a 4% interest bearing promissory note that the term is 1 year. As of December 31, 2019, the Company recorded notes payable – related party of $50,000 and accrued interest of $809.

PROVISION FOR INCOME TAXES

PROVISION FOR INCOME TAXES	12 Months Ended
	Dec. 31, 2019
PROVISION FOR INCOME TAXES
11. PROVISION FOR INCOME TAXES	The Company provides for income taxes under ASC 740, “Income Taxes.” The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 21% to the net loss before provision for income taxes for the following reasons: December 31, December 31, 2019 2018 Net operating loss $ (58,560 ) $ (147,469 ) Valuation allowance 58,560 147,469 Income tax expense per books $ - $ - The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows: December 31, December 31, 2019 2018 NOL Carryover $ 206,029 $ 147,469 Valuation allowance (206,029 ) (147,469 ) Net deferred tax asset $ - $ - Due to the change in ownership provisions of the Income Tax laws of United States of America, net operating loss carry forwards of approximately $981,000 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.

COMMITMENT

COMMITMENT	12 Months Ended
	Dec. 31, 2019
COMMITMENT
12. COMMITMENT	On March 30, 2018, the Company entered into a rental agreement with Ridge II Properties for the corporate office. Monthly rent is $1,000. The term of the lease is one year, beginning April 1, 2018 to March 31, 2019. During the year ended December 31, 2019 and 2018, the Company incurred $2,724 and $13,651, respectively.

SUSEQUENT EVENT

SUSEQUENT EVENT	12 Months Ended
	Dec. 31, 2019
SUSEQUENT EVENT
13. SUBSEQUENT EVENT	On February 6, 2020, the Company established its Series A Preferred Stock, par value .0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock (the “Shares”). The Company may use the Shares for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Shares have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio. On February 6, 2020, the Company’s board and a majority of its shareholders approved an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of its common stock, par value .0001, from 100,000,000 shares to 200,000,000 shares. The increase will become effective March 19, 2020.

SUMMARY OF SIGNIFICANT POLICI_2

SUMMARY OF SIGNIFICANT POLICIES (Policies)	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT POLICIES
Basis of presentation	The Company represents its consolidated financial statements were prepared in accordance with US GAAP and the rules of the Securities and Exchange Commission and that, in the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations are historical and not necessarily indicative of the results to be expected for any future period.
Consolidation	The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Blenders Choice Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”
Use of estimates	The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high credit quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value. As of December 31, 2019, and 2018, the Company has no cash equivalents.
Investment Securities	In January 2016, the FASB issued ASU 2016-01, Financial Instruments — Overall: Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), which addresses certain aspects of the recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 was effective for the Company beginning January 1, 2018 and we are now recognizing any changes in the fair value of certain equity investments in net income as prescribed by the new standard rather than in other comprehensive income ("OCI"). We recognized a cumulative effect adjustment to increase the opening balance of accumulative deficit as of January 1, 2018 by $58,336. Equity securities are classified as available for sale. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. In accordance with Accounting Standards Codification (“ASC”) 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.
Earnings (loss) per share	Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. There were no potentially dilutive securities outstanding during the periods presented.
Revenue recognition	Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied.
Cost of revenue	Cost of revenue includes the inventory purchased from a related party.
Inventory	Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at December 31, 2019 and 2018, the Company determined that no reserve was required.
Stock-based compensation	The Company accounts for stock-based compensation arrangements with employees, nonemployee directors and consultants using a fair value method, which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options, on a straight-line basis over the requisite service period in the Company’s consolidated statements of operations. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant.
Financial Instruments and Fair Value Measurements	As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level at December 31, 2019 and 2018, measured at fair value on a recurring basis: Fair Value Measurements as of December 31, 2019 Using: Total Carrying Value as of December 31, Quoted Market Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs 2019 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 772 $ 772 $ - $ - Liabilities Derivative liabilities $ 464,024 464,024 Fair Value Measurements as of December 31, 2018 Using: Total Carrying 2018 Quoted Market Significant Other (Level 2) Significant (Level 3) Assets: Equity Securities $ 3,987 $ 3,987 $ - $ - Liabilities Derivative liabilities $ 662,038 $ - $ - $ 662,038
Derivative Financial Instruments	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Concentration of credit risk	Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.
Income taxes	The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more- likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives. The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the financial results of operations improve, and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance. Significant judgment is required in evaluating the Company’s tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.

SUMMARY OF SIGNIFICANT POLICI_3

SUMMARY OF SIGNIFICANT POLICIES (Tables)	12 Months Ended
	Dec. 31, 2019
SUMMARY OF SIGNIFICANT POLICIES
Schedule of fair value of measurements of assets on recurring basis	Fair Value Measurements as of December 31, 2019 Using: Total Carrying Value as of December 31, Quoted Market Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs 2019 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 772 $ 772 $ - $ - Liabilities Derivative liabilities $ 464,024 464,024 Fair Value Measurements as of December 31, 2018 Using: Total Carrying 2018 Quoted Market Significant Other (Level 2) Significant (Level 3) Assets: Equity Securities $ 3,987 $ 3,987 $ - $ - Liabilities Derivative liabilities $ 662,038 $ - $ - $ 662,038

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2019
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Schedule of accounts payable and accrued liabilities	December 31, December 31, 2019 2018 Accounts payable $ 1,297 $ 39,724 Credit card 20,214 719 Accrued interest 2,457 8,185 Accrued liabilities 5,986 5,323 $ 29,954 $ 53,951

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Dec. 31, 2019
CONVERTIBLE NOTES
Schedule of convertible notes	December 31, December 31, 2019 2018 Convertible Notes - originated in April 2018 $ 95,000 $ 95,000 Convertible Notes - originated in June 2018 166,000 166,000 Convertible Notes - originated in October 2018 50,000 50,000 Convertible Notes - issued fiscal year 2019 73,500 - Total convertible notes payable 384,500 311,000 Less: Unamortized debt discount (71,607 ) (223,189 ) Total convertible notes 312,893 87,811 Less: current portion of convertible notes 312,893 - Long-term convertible notes $ - $ 87,811

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2019
DERIVATIVE LIABILITIES
Schedule of estimated fair values of the liabilities measured on a recurring basis	Year Ended Year ended December 31, December 31, 2019 2018 Expected term 0.22 - 1.43 years 1.22 - 2.01 years Expected average volatility 229% - 320% 265% - 309% Expected dividend yield - - Risk-free interest rate 1.55% - 2.40% 2.27% - 2.88%
Schedule of changes in the derivative liabilities	Fair Value Measurements Using Significant Observable Inputs (Level 3) Balance - December 31, 2017 $ - Addition of new derivatives recognized as debt discounts 403,790 Addition of new derivatives recognized as loss on derivatives 452,943 Settled on issuance of common stock (285,568 ) Reclassification from APIC to derivative due to tainted instruments 42,196 Loss on change in fair value of the derivative 48,677 Balance - December 31, 2018 $ 662,038 Gain on change in fair value of the derivative (198,014 ) Balance - December 31, 2019 $ 464,024
Schedule of (gain) loss on derivatives	Year Ended December 31, 2019 2018 Day one loss due to derivative liabilities on convertible notes $ - $ 452,943 (Gain) loss on change in fair value of the derivative liabilities (198,014 ) 48,677 $ (198,014 ) $ 501,620

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2019
STOCKHOLDERS' EQUITY
Schedule of outstanding and exercisable stock options	Warrants Outstanding Warrants Exercisable Number of Contractual life Number of Shares (in years) Exercise Price Shares Exercise Price 200,000 0.22 $ 0.10 200,000 $ 0.10

PROVISION FOR INCOME TAXES (Tab

PROVISION FOR INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2019
PROVISION FOR INCOME TAXES
Schedule of statutory fedral income tax rate	December 31, December 31, 2019 2018 Net operating loss $ (58,560 ) $ (147,469 ) Valuation allowance 58,560 147,469 Income tax expense per books $ - $ -
Schedule of net deferred tax	December 31, December 31, 2019 2018 NOL Carryover $ 206,029 $ 147,469 Valuation allowance (206,029 ) (147,469 ) Net deferred tax asset $ - $ -

DESCRIPTION OF BUSINESS AND H_2

DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative)	12 Months Ended
	Dec. 31, 2019
DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative)
State of Incorporation	Delaware
Date of Incorporation	Apr. 19, 2013

SUMMARY OF SIGNIFICANT POLICI_4

SUMMARY OF SIGNIFICANT POLICIES (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Assets
Equity Securities	$ 772	$ 3,987
Fair Value, Measurements, Recurring [Member]
Assets
Equity Securities	772	3,987
Liabilities
Derivative liabilities	464,024	662,038
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Equity Securities	772	3,987
Liabilities
Derivative liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Equity Securities	0	0
Liabilities
Derivative liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Equity Securities	0	0
Liabilities
Derivative liabilities	$ 464,024	$ 662,038

SUMMARY OF SIGNIFICANT POLICI_5

SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash and short term investment maturity description	Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days
Description of tax benefit measurement	To measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations
Accumulative deficit	$ (4,758,917)	$ (4,519,990)
Blenders Choice Inc [Member]
Ownership Percentage	100.00%
Cumulative Effect Adjustment [Member] | January 1, 2018 [Member]
Accumulative deficit	$ 58,336

GOING CONCERN (Detail Narrative

GOING CONCERN (Detail Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
GOING CONCERN (Detail Narrative)
Accumulated deficit	$ (4,758,917)	$ (4,519,990)

MARKETABLE SECURITIES (Detail N

MARKETABLE SECURITIES (Detail Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Marketable securities	$ 772	$ 3,987
Hemp Inc [Member]
Equity securities held	105,736	105,736

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable	$ 1,297	$ 39,724
Credit card	20,214	719
Accrued interest	2,457	8,185
Accrued liabilities	5,986	5,323
Accounts Payable And Accrued Liabilities	$ 29,954	$ 53,951

CONVERTIBLE NOTES (Details)

CONVERTIBLE NOTES (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total convertible notes payable	$ 384,500	$ 311,000
Less: Unamortized debt discount	(71,607)	(223,189)
Total convertible notes	312,893	87,811
Less: current portion of convertible notes	312,893
Long-term convertible notes		87,811
Convertible Notes Payable [Member] | Originated In April Two Thousand Eighteen [Member]
Total convertible notes payable	95,000	95,000
Convertible Notes Payable [Member] | Originated In June Two Thousand Eighteen [Member]
Total convertible notes payable	166,000	166,000
Convertible Notes Payable [Member] | Originated In October Two Thousand Eighteen [Member]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable [Member] | Issued fiscal year Two Thousand Nineteen [Member]
Total convertible notes payable	$ 73,500

CONVERTIBLE NOTES (Detail Narra

CONVERTIBLE NOTES (Detail Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization of debt discount	$ 158,082	$ 202,811
Interest Expense	(199,319)	(247,885)
Accrued interest	256
Proceeds from Convertible notes	$ 67,000	$ 426,000
Convertible Notes Payable [Member]
Description of conversion price	Conversion prices are 58% multiplied by the lowest trading price during the 20 trading day period ending on the latest complete training day prior to the conversion date.	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price
Interest Expense	$ 39,457	$ 45,074
Accrued interest	1,391	8,183
Principal amount of convertible notes	73,500	426,000
Proceeds from Convertible notes	$ 67,000	$ 426,000
Number of common shares for debt conversion		107,000
Value of common shares for debt conversion		$ 22,210
Convertible debt term	1 year	2 years
Annual interest rates	10.00%	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Convertible at 180 days from issuance

DERIVATIVE LIABILITIES (Details

DERIVATIVE LIABILITIES (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Expected term	2 months 19 days	1 year 2 months 19 days
Expected average volatility	229.00%	265.00%
Risk-free interest rate	1.55%	2.27%
Maximum [Member]
Expected term	1 year 5 months 5 days	2 years 4 days
Expected average volatility	320.00%	309.00%
Risk-free interest rate	2.40%	2.88%

DERIVATIVE LIABILITIES (Detai_2

DERIVATIVE LIABILITIES (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
DERIVATIVE LIABILITIES (Details 1)
Beginnig Balance	$ 662,038
Addition of new derivatives recognized as debt discounts		$ 403,790
Addition of new derivatives recognized as loss on derivatives		452,943
Settled on issuance of common stock		(285,568)
Reclassification from APIC to derivative due to tainted instruments		42,196
Gain on change in fair value of the derivative	(198,014)	48,677
Ending Balance	$ 464,024	$ 662,038

DERIVATIVE LIABILITIES (Detai_3

DERIVATIVE LIABILITIES (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
DERIVATIVE LIABILITIES
Day one loss due to derivative liabilities on convertible notes	$ 0	$ 452,943
(Gain) loss on change in fair value of the derivative liabilities	(198,014)	48,677
Aggregate (gain) loss on derivatives	$ (198,014)	$ 501,620

NOTE PAYABLE (Detail Narrative)

NOTE PAYABLE (Detail Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Notes Payable	$ 7,218
Accrued interest	256
Repayment Of Notes Payable	(8,582)
Interest expense	(199,319)	$ (247,885)
Third Party [Member] | Notes Payable, Other Payables One [Member] | October 24, 2019 [Member]
Notes Payable	3,900
Repayment Of Notes Payable	4,212
Repayment of debt	709
Interest expense	$ 59
Term of notes payable	5 months 30 days
Third Party [Member] | Notes Payable, Other Payables [Member] | August 1, 2019 [Member]
Notes Payable	$ 11,900
Repayment Of Notes Payable	12,852
Repayment of debt	8,588
Interest expense	$ 656
Term of notes payable	5 months 30 days

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
STOCKHOLDERS' EQUITY
Number of Warrants Outstanding | shares	200,000
Warrants Outstanding Contractual life	2 months 19 days
Warrants Outstanding Exercise Price | $ / shares	$ 0.10
Number of Warrants Exercisable | shares	200,000
Warrants Exercisable Exercise Price | $ / shares	$ 0.10

STOCKHOLDERS'EQUITY (Detail Nar

STOCKHOLDERS'EQUITY (Detail Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, shares authorized		5,000,000	5,000,000
Preferred stock, par value (in dollars per share)		$ .0001	$ .0001
Preferred stock, shares issued		0	0
Common stock, shares authorized		100,000,000	100,000,000
Common stock, par value (in dollars per share)		$ .0001	$ .0001
Common stock, shares issued		18,576,379	18,096,169
Common stock, shares outstanding		18,576,379	18,096,169
Stock Issued During Period, Shares, New Issues			$ 2,038,975
Common Stock, shares issuable, shares		362,390	275,502
Warrants outstanding aggregate intrinsic value		$ 7,720
Warrants closing market price		$ 0.1386
Common stock shares issued, amount
Common stock, shares issued, amount			$ 101,995
Warrants term		2 months 19 days
Number of Warrants Outstanding		200,000
Exercise Price		$ 0.10
Consultant Agreement [Member]
Warrants term			2 years
Number of Warrants Outstanding			200,000
Exercise Price			$ 0.1
Warrant expense			$ 52,365
Consulting Service [Member]
Common Stock, shares issuable, shares		70,758
Cancellation of shares		70,758
Common stock, shares issued, shares			231,975
Common stock, shares issued, amount			$ 44,095
Unrelated Party [Member]
Common Stock, shares issuable, shares			1,250,000
Subscription receivable			$ 100,000
Cancellation of shares	1,250,000
Dr. Edward Jacobs [Member]
Common stock, restricted shares issued for compensation		480,210
Convertible Notes [Member]
Common Stock, shares issued for debt conversion, shares			107,000
Common Stock, shares issued for debt conversion, amount			$ 22,110
Employment Agreement [Member]
Common stock shares issued, shares			450,000
Common stock shares issued, amount			$ 83,325
Employment Agreement [Member] | Related Party Transaction [Member]
Common Stock, shares issuable, shares		352,390
Common Stock, shares issuable, amount		$ 42,000

RELATED PARTY TRANSACTION (Deta

RELATED PARTY TRANSACTION (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2020	Aug. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Oct. 31, 2018
Notes payable, related party			$ 50,000
Accrued interest			809
Cash					$ 7,000
Stock based compensation			92,792	$ 272,685
Accrued interest			256
Gain on sale of asset				32,000
Dr. Edward Jacobs [Member]
Notes payable issued			$ 50,000
Rate of interest			4.00%
Term of note			1 year
Sale of Trade Mark [Member] | Ferris Holding [Member] | Excel Dog [Member]
Sales consideration for Trade mark, research and videos				32,000
Gain on sale of asset				$ 32,000
June 2018 [Member] | Employment Agreement [Member] | Dr. Edwards E. Jacobs [Member]
Base Compensation per month			$ 10,000
Common stock shares issued, shares			100,000
Common stock shares issued, value			$ 27,500
Stock based compensation			8,792
August 2019 [Member] | Employment Agreement [Member] | Robert W. Ellis [Member]
Stock based compensation			8,792
Accrued interest			5,000
August 2019 [Member] | Employment Agreement [Member] | Robert W. Ellis [Member] | Subsequent Event [Member]
Base Compensation per month		$ 5,000
Common stock shares issued, shares		250,000
Common stock shares issued, value		$ 26,375
September 2019 [Member] | Employment Agreement [Member] | Ronald Lambrecht [Member] | Subsequent Event [Member]
Base Compensation per month	$ 5,000
Common stock shares issued, shares	100,000
Common stock shares issued, value	$ 11,010
June 1, 2014 [Member] | Ferris Holding [Member] | Rental Agreement [Member]
Rent Payable			$ 1,500
Term of lease			1 year
Lease Agreement Description			The Company entered into a new rental agreement with Ferris for the corporate office. Monthly rent is $1,500

PROVISION FOR INCOME TAXES (Det

PROVISION FOR INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
PROVISION FOR INCOME TAXES
Net operating loss	$ (58,560)	$ (147,469)
Valuation allowance	58,560	147,469
Income tax expense per books

PROVISION FOR INCOME TAXES (D_2

PROVISION FOR INCOME TAXES (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
PROVISION FOR INCOME TAXES
NOL Carryover	$ 206,029	$ 147,469
Valuation allowance	(206,029)	(147,469)
Net deferred tax asset

PROVISION FOR INCOME TAXES (D_3

PROVISION FOR INCOME TAXES (Details Narrative)	Dec. 31, 2019USD ($)
PROVISION FOR INCOME TAXES (Details Narrative)
Net operating loss carry forwards	$ 981,000

COMMITMENT (Details Narrative)

COMMITMENT (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Rent expenses		$ 2,724	$ 13,651
Rental Agreement [Member] | Ridge II Properties [Member]
Rent payable per month	$ 1,000
Description of rental agreement	Rental agreement with Ridge II Properties for the corporate office. Monthly rent is $1,000. The term of the lease is one year, beginning April 1, 2018 to March 31, 2019

SUBSEQUENT EVENT (Details Narra

SUBSEQUENT EVENT (Details Narrative) - $ / shares	Feb. 06, 2020	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, shares designated		5,000,000	5,000,000
Minimum [Member]
Expected term		2 months 19 days	1 year 2 months 19 days
Subsequent Event [Member] | Series A Preferred Stock [Member]
Preferred stock, shares designated	4,000,000
Preferred stock, per share price	$ .0001
Description of stock conversion	The Shares have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio
Description of amedment in Article of incorporation	The Company’s board and a majority of its shareholders approved an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of its common stock, par value .0001, from 100,000,000 shares to 200,000,000 shares. The increase will become effective March 19, 2020